The sudden onset of stroke is devastating and leads to temporary and/or permanent disability to speech, sensation, memory and motor neuron damage. The damage is caused by a bleeding or blocked cerebral blood vessel leading to local brain damaged areas with loss of neurons and glial cells.
No effective therapy exists and therefore any stem cell treatment that may offer improvement would be greatly welcomed. With the discovery of Mexico stem cell therapy has come new hope.
Although there are niches and reservoirs of stem cells in the adult brain their numbers are not sufficient to restore neurological function. The umbilical cord blood has stem cells that are pluripotent in their ability to be transformed into many precursor cells of various organs in the body including the brain.
Umbilical cord blood stem cells when placed into culture with nerve growth factor, brain neurotrophic factor and nutrients can form precursor progenitor brain stem cells.
Patients with post stroke syndrome (even for many years) can be given intravenous brain stem cells with stem cell therapy, oligodendrocytes to replace myelin and neuron stem cells. These cells will home (migrate) to areas of damaged brain tissue with hopes of stem cell treatment functional recovery.
Stem cell treatment and stem cell therapy abroad at the Biogenetics Institute, offers alternative cancer treatments as well as stem cell treatment for diabetes, lupus, heart disease, Parkinson’s and other disease.
Although there are niches and reservoirs of stem cells in the adult brain their numbers are not sufficient to restore neurological function. The umbilical cord blood has stem cells that are pluripotent in their ability to be transformed into many precursor cells of various organs in the body including the brain.
Stem cell treatment and stem cell therapy abroad at the Biogenetics Institute, offers alternative cancer treatments as well as stem cell treatment for diabetes, lupus, heart disease, Parkinson’s and other disease.
For more details visit: http://www.biogenetictreatment.com/
Systemic lupus is a major disorder that may cause damage to the skin, bone marrow, kidneys, heart, joints, immune system and brain by inflammation.
There are many treatments that are available to treat lupus but eventually the condition may progress to cause major health disability. In patients that are getting progressively worse despite treatment, patients should consider the use of stem cell therapy abroad or stem cell treatment abroad Mexico. There are two major forms of treatment in dealing with this disabling autoimmune disorder:
1. The use of autologous (self) stem cells derived from the patient’s own peripheral blood or bone marrow.
The use of stem cells derived from umbilical cord blood and then administered intravenously into the patient. Umbilical cord blood stem cells are far more potent as compared to adult autologous stem cells.
Patients with severe forms of lupus have limited treatment options that offer temporary relief of symptoms. For these patients, stem cell therapy abroad or stem cell treatment abroad Mexico may offer potential effective treatment for a normal functioning immune system.
Stem cell treatment and stem cell therapy abroad at the Biogenetics Institute, offers alternative cancer treatments as well as stem cell treatment for diabetes, lupus, heart disease, Parkinson’s and other disease.
Stem cell treatment and stem cell therapy abroad at the Biogenetics Institute, offers alternative cancer treatments as well as stem cell treatment for diabetes, lupus, heart disease, Parkinson’s and other disease. For more details visit: http://www.biogenetictreatment.com/
Stem cell treatment and stem cell therapy abroad at the Biogenetics Institute, offers alternative cancer treatments as well as stem cell treatment for diabetes, lupus, heart disease, Parkinson’s and other disease.
For more details visit: http://www.biogenetictreatment.com/
The International Society for Stem Cell Research (ISSCR) Launches Web Site Providing Information on Stem Cell Treatments
Deerfield, IL (PRWEB) June 8, 2010 –
The International Society for Stem Cell Research (ISSCR) announced today that it has launched “A Closer Look at Stem Cell Treatments” (http://www.closerlookatstemcells.org), a Web site to arm patients, their families and doctors with information they need to make decisions about stem cell treatments. The Web site was developed in response to the growing number of aggressive marketing campaigns on the Internet and elsewhere offering stem cell treatments. The ISSCR urges individuals to be cautious and to learn the facts before making any decision.
“Stem cells do hold tremendous promise for the treatment of many serious diseases. Yet there are organizations out there that are preying on patients’ hopes, offering stem cell treatments – often for large sums of money – for conditions where the current science simply does not support its benefit or safety,” said Irving Weissman, MD, President of the ISSCR. “We want to stress through this initiative that there are internationally accepted medical criteria for getting new medicines into clinics. Patients have a right to know if the clinic or treatment they are considering adheres to these criteria. We feel it is an obligation of the ISSCR to both a) alert patients and caregivers about clinics and other entities that are selling unproven ‘stem cell’ therapies, and b) help shepherd real stem cell advances from discovery to successful patient treatments as rapidly as possible. ”
Currently there are only a small number of stem cell treatments that have been shown to be beneficial in rigorous studies. These mostly pertain to diseases or conditions of the blood as well as skin grafts and corneal repair. The ISSCR is concerned that stem cell treatments are being marketed to patients worldwide for a variety of medical conditions, without having the mechanisms in place to ensure safety or likely benefit. Without these safeguards, patients may be put at risk.
A Closer Look at Stem Cell Treatments offers several tools for patients to evaluate a prospective clinic or treatment including a list of questions to ask about the treatment and providers as well as resources that explain fundamental scientific principles of stem cell biology and the implications for stem cell treatments. Ultimately, the Web site will list stem cell clinics and whether they do or do not provide the ISSCR with information showing that appropriate oversight and other patient protections are in place.
Visitors to www.closerlookatstemcells.org can submit, for review, a clinic or treatment they have seen advertised. The treatment providers will be asked to present evidence that a) a medical ethics committee is involved to protect patients’ rights; and b) there is supervision by an official regulatory body such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) for the trial or approved use of a treatment for specific diseases or conditions.
“We want patients to feel they have access to critical information they might otherwise not have, so they can make the best decision for their individual situation,” said Patrick Taylor, JD, Chair of the ISSCR Task Force on Unproven Stem Cell Treatments. “The key to ensuring that treatments are safe and effective is a well-established path from basic research to clinical care, through carefully constructed studies and independent review. The criteria selected by the task force are simple to apply, but of extraordinary power in promoting progress while protecting patients.”
The International Society for Stem Cell Research (ISSCR) is an independent, nonprofit organization established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell research and application.
Shirdesh has Retinopathy of Prematurity (ROP) and came to China for adult stem cell therapy. He received several transplants of non-embryonic umbilical cord blood blood stem cells. Therapy was delivered by the medical staff at Bethune International Peace Hospital. International patient services were provided by Beike Biotech.
Rusty Leech, of Rusty Without Wheels, is a paraplegic who has received stem cell treatments in India. His progress is another example of how stem cells can successfully regenerate damaged tissue. He shared his story this week in an interview on American Public Media.
Rusty, 52, has been a paraplegic for more than 10 years. An accident in 1998 left him paralyzed from the middle of his back down. When he learned about India’s Dr. Geeta Shroff, who performed embryonic stem cell therapy with successful results, Rusty decided it was worth the effort to raise money for the treatment and the trip to India.
“We couldn’t help but trust and believe . . . That leap of faith is still taking me onward and upward.”
Since late 2007 Rusty has been to India three times for treatment. He says it’s definitely making a difference. Rusty has gained new nerve sensation and some physical functions. He began to have different feelings in the parts of his body that had been paralyzed for more than a decade. “My body continues to miraculously improve,” says Rusty.
The travel and treatments are financially draining. Thus far, Rusty’s family and friends have rallied to help him raise funds for his expenses. He knows that kind of help can’t be expected, especially amid this difficult economy.
Rusty’s advice to others who face challenges like this: “Don’t give up hope! Instead, look forward to wellness.”
To hear Rusty’s interview on American Public Media, visit:
Stem Cells: The science, the benefits, the debate, and the future
While President Obama recently lifted the ban on federal funding for embryonic stem cell research imposed by President Bush eight years ago, some people continue to oppose this move and call it unethical. So, while the scientific community is thrilled by the news and says the research will lead to medical breakthroughs, some communities consider the research as a “slippery slope”. But, what exactly are stem cells and why are they so important as to generate hot debates among all sorts of circles - political, social, religious, and what not? Here’s a look at some of those details.
The science behind stem cells What sets stem cells apart from other cells is their ability to turn into any other type of tissue in the body. A stem cell from the bone marrow, for example, can be transformed into a neuron or nerve cell in the brain.
Types of stem cells: Embryonic stem cells versus Adult stem cells Broadly, there are two types of stem cells in humans - embryonic stem cells and non-embryonic stem cells. Embryonic stem cells (ESC), as the name suggests, are isolated from the inner cell mass of an early stage embryo (4-5 days post fertilization, and consisting of 50-150 cells). On the other hand, non-embryonic stem cells which are also known as adult stem cells are found in adult tissues. Embryonic stem cells are pluripotent as opposed to adult stem cells that are multipotent. What this means is that embryonic stem cells can differentiate into any of the more than 220 cell types in the adult body (to be able to give rise to any mature cell type) while adult stem cells can only form a limited number of cell types (closely related family of cells).
Utility of stem cells The importance of stem cell lies in the fact that they can be converted into any type of other cells or tissues in the body – neurons, pancreatic tissue, heart muscle cells, etc. So, for example, stem cells harvested from your bone marrow can possibly be used to repair the damage in your heart muscle caused during a heart attack, or to correct blood disorders such as sickle cell anemia (anaemia) through transfusions of stem cells. Stem cell therapy is believed to have the potential to dramatically change the treatment of human disease. Embryonic stem (ES) cell therapies have been proposed for regenerative medicine and tissue replacement after injury or disease. But, it should be noted at this point that embryonic stem cell therapies are not in use yet. They are still only in the stage where medical researchers are testing them on animals. On the other hand, adult stem cells have been successfully used to treat leukemia (leukaemia) and related bone/blood cancers utilizing bone marrow transplants.
The controversy The controversy behind stem cell research pertains only to human embryonic stem cell research and not all stem cell research. What is controversial is the fact that the source of the research material, human embryos, is destroyed in the process of harvesting the stem cells. Pro-life activists oppose the research arguing that a human embryo is a human life that is entitled to protection. Another area of controversy is that embryonic stem cell technologies are a slippery slope that may lead to reproductive cloning which may devalue human life. The production of adult stem cells, on the other hand, does not require the destruction of an embryo and therefore, adult stem cell research and therapy are not as controversial. Though, adult stem cell treatment does carry a risk of rejection by the body’s immune system.
The present state of stem cell research There are some countries that offer treatments using stem cells (read about medical tourism) but in such therapies only adult stem cells derived from the patient’s body are used (autograft). When possible, autografts are preferred as they remove the risk of rejection by the recipient’s body. There is promising research ongoing in the field of stem cells to derive treatments for a wider variety of diseases including cancer, Parkinson’s disease, spinal cord injuries, diabetes, heart disease, Alzheimer’s disease, Amyotrophic lateral sclerosis or ALS (Lou Gehrig’s disease), multiple sclerosis, lung disease, arthritis, organ failure, and muscle damage, amongst a number of other impairments and conditions.
The future The ultimate question on the minds of many is – “Why can’t we simply use adult stem cells instead of harvesting embryonic stem cells?” Theoretically, embryonic stem cells are considered better because they work as a biological blank slate and are the most versatile of all stem cells whereas adult stem cells are sort of semi-specialized cells and are not as versatile as ESCs. Though the field of adult stem cells is not marred by controversies, the problem with adult stem cells is also that they are often present only in minute quantities, are difficult to isolate and purify, and their numbers may decrease with age, according to a primer by the National Institutes of Health (NIH). At this juncture, much remains unknown about the potential of embryonic stem cells. But, going by the success in the field of animal testing it may very well turn out that embryonic stem cells could provide solutions to many diseases in humans. The answer to the potential benefits of ESC lies in research. To understand the benefits of embryonic stem cells or any type of stem cells for that matter, and to discover possible treatments in humans, various lines of research need to be pursued simultaneously. Only research can prove if adult stem cells are better over embryonic stems cells for curing human diseases or vice versa. It may also emerge that adult stem cells offer good treatments for certain ailments, while embryonic stem cells are better for curing others.
About the author:
The author works for Healthbase (www.healthbase.com), a medical tourism facilitator that connects patients to high quality healthcare in USA and abroad for a fraction of the typical cost of care in US, Canada and UK.
56 years old patient of hemiplegia treated by Cord and Bone Marrow Stem Cell at Chaitanya stem cell center Pune India.This video demonstrate that Stem cell Effectively repairs and regenerate Old brain damage. Video Rating: 0 / 5
Advancements in gene therapy have provided useful data, which has helped in understanding the pathogenesis of diseases. The discipline heralds a significant potential for the biotechnology industry over the next 20 years, as the approach moves from research labs to clinical trials. Proteins and monoclonal antibodies have revolutionized the treatment of a wide variety of diseases, and gene-based therapies that deliver the DNA sequences encoding proteins and antibodies signify the next big step in the evolution of biopharmaceuticals.
Gene therapy market is still in the experimental stages with success yet to be achieved in developing completely curative therapeutic drugs, as stated in a recent report published by Global Industry Analysts, Inc. Till date, only one gene therapy drug Gendicine, developed by Shenzhen SiBiono Gene Technologies Co., has been approved, which is marketed in China. Market predictions for gene therapy highly depend on the regulatory approval of products currently in clinical trials. Most gene therapy products for cancer and cardiovascular diseases are in Phase III/ Phase II of clinical trials. Cost of the treatment and disease population are the other factors that affect the gene therapy market. Funding and research developments and acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future.
Gene therapy industry comprises of biotech, pharmaceutical companies, research, and academic institutions. Leading biotech companies operating in gene therapy marketplace include AnGes MG Inc, Cell Genesys, GenVec, Genzyme Corporation, Introgen Therapeutics Inc, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd, Targeted Genetics Corp, Transgene, Urigen Pharmaceuticals Inc., and Vical.
The report, titled “Gene Therapy: A Global Strategic Business Report” published by Global Industry Analysts, Inc., provides comprehensive insight into the industry dynamics, and highlights noteworthy market drivers, challenges, and trends shaping the market. The report also enumerates recent industry developments, and outlines the gene therapy products under development. Analysis is provided for the period 2007-2015.
For more details about this research report, please visit http://www.strategyr.com/Gene_Therapy_Market_Report.asp.
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.
